US Executive Compensation Proxy SEC Filings — May 27, 2026

27-05-2026

Gates Industrial Corp plc is proposing a redomiciliation from England and Wales to Bermuda via a scheme of arrangement, which will be voted on by shareholders. The Board cites increased strategic flexibility, streamlined share buybacks, enhanced dividend capacity, elimination of duplicative regulation, and estimated annual cash savings of approximately $4 million as key benefits. However, the redomiciliation introduces governance changes such as eliminating supermajority vote requirements and pre-emption rights, which may reduce certain shareholder protections.

• · The redomiciliation is not tax-driven; operating subsidiaries' tax residence will not change.
• · Redomiciliation is expected to be tax-free to U.S. Holders.
• · New Gates will not have a shareholder rights plan (poison pill) in place upon redomiciliation and commits that any future plan adopted without shareholder approval will automatically terminate after one year unless approved.
• · Enhanced governance protections for certain related party transactions: an Independent Committee must evaluate and negotiate Covered Transactions proposed by a Controlled Acquiror, and shares held by the Controlled Acquiror are excluded from quorum and voting.
• · The Board considered redomiciling to the United States (including Delaware) but chose Bermuda due to lower cost, greater certainty, and more favorable tax regime.
• · Under English law, share buyback approvals must be renewed every five years or more frequently; Bermuda offers greater flexibility.
• · U.K. stamp duty of 0.5% on buybacks would be eliminated after redomiciliation.
• · Dividend payments under English law require sufficient distributable reserves; Bermuda only requires a solvency test.
• · The Company will report solely under U.S. GAAP after redomiciliation, eliminating duplicative IFRS reporting.

27-05-2026

Nukkleus Inc. (now T3 Defense Inc.) filed a definitive proxy statement (DEF 14A) for a special meeting on June 18, 2026, seeking stockholder approval for four proposals: (1) issuance of up to 14,084,506 shares upon exercise of warrants, (2) issuance of shares upon conversion of Series B Preferred Stock (up to 9,389,600 shares at $2.13 per share) above the 20% exchange cap, (3) a reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid price requirement (the stock was trading below $1.00 and received a non-compliance notice on May 5, 2026), and (4) adjournment if needed to solicit additional votes. The company raised $20 million via a February 24, 2026 private placement of 400 units of Series B Preferred Stock and warrants. The board recommends voting 'FOR' all proposals.

• · The company received a Nasdaq non-compliance notice on May 5, 2026 for failing to maintain the $1.00 minimum bid price.
• · The February 2026 private placement involved 400 units at $50,000 each, totaling $20 million.
• · Each unit consisted of one restricted share of Series B Preferred Stock and 1.5 restricted warrants to purchase up to 35,211 shares of Common Stock.
• · The initial conversion price for Series B Preferred Stock is $2.13 per share, subject to adjustment upon stockholder approval and other events.
• · As of the record date, there were 60,270,525 shares of Common Stock outstanding and 200 shares of Preferred Stock outstanding.
• · The quorum requirement is 20,756,842 votes (one-third of total voting power).
• · Proposals One, Two, and Four are non-routine; Proposal Three (reverse split) is routine and allows broker discretionary voting.
• · The board recommends voting 'FOR' all four proposals.

27-05-2026

Capital Southwest Corporation filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Shareholders to be held virtually on July 22, 2026. Proposals include the election of six directors, an advisory vote on executive compensation ('Say on Pay'), approval of the frequency of advisory votes on executive compensation (recommended 'ONE YEAR'), approval of a charter amendment to increase authorized shares of common stock, and ratification of RSM US LLP as independent auditor for FY 2027. While the proxy provides standard governance updates, no specific financial performance metrics or standout compensation figures are mentioned in the filing content provided.

27-05-2026

Gloo Holdings, Inc. filed its DEF 14A proxy statement on May 27, 2026, for the 2026 annual meeting of stockholders. The board of directors consists of eight members, five of whom are independent, with three classes serving staggered three-year terms. The filing details the nominees for Class I directors (Bishop Claude Alexander Jr., John Furst, Derek Green) and provides biographical information for all directors, including the recent appointment of Patrick Gelsinger as Executive Chair and head of technology in March 2025.

• · The board is divided into three classes with staggered three-year terms; Class I directors are up for election at the 2026 annual meeting.
• · Patrick Gelsinger joined as Executive Chair and head of technology in March 2025, overseeing Gloo AI, Gloo Workspace, Gloo Media Network, and Gloo360.
• · Robert Gruenewald joined the board in January 2025; Elizabeth Grennan joined in April 2025.
• · The company uses 'householding' to deliver a single copy of proxy materials to stockholders sharing an address.
• · Proxy materials are available at www.virtualshareholdermeeting.com/GLOO2026.

27-05-2026

Caring Brands, Inc. filed a DEF 14A proxy statement for a Special Meeting to vote on four proposals: (1) approval of an Additional Investment Right, (2) issuance of Series A Preferred shares, (3) amendment to increase authorized common stock from 100 million to 500 million shares, and (4) adjournment to solicit additional proxies. The Board unanimously recommends voting 'FOR' all proposals. As of the record date, 9,091,506 common shares were outstanding; the increase would authorize approximately 470 million additional shares for future capital raising, acquisitions, and compensation, potentially diluting existing stockholders.

• · The Board unanimously recommends a vote 'FOR' all four proposals.
• · No immediate arrangements for issuance of additional shares other than the Securities Purchase Agreement.
• · The amendment is not intended as an anti-takeover measure.
• · No broker non-votes are expected for any proposal.
• · If quorum is not met, abstentions and broker non-votes count as 'AGAINST'.

27-05-2026

Planet Labs PBC filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Stockholders to be held virtually on July 9, 2026. The meeting will consider the re-election of three Class II directors (Vijaya Gadde, General John W. Raymond, and Scott Reese), ratification of KPMG LLP as independent auditor for fiscal year ending January 31, 2027, and a non-binding advisory vote on named executive officer compensation. As of the record date (May 15, 2026), the company had 332,899,400 shares of Class A common stock and 23,493,796 shares of Class B common stock outstanding.

• · The annual meeting will be held virtually at www.virtualshareholdermeeting.com/PL2026.
• · The record date for voting is May 15, 2026.
• · The proxy materials are available at http://www.proxyvote.com and investors.planet.com.
• · The board recommends voting FOR all three proposals.

27-05-2026

Cocrystal Pharma, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders to be held virtually on July 14, 2025 (note: year appears inconsistent). The meeting will address the election of directors, ratification of independent auditors, and adjournment. As of the record date May 19, 2026, there were 13,787,453 shares of common stock outstanding and entitled to vote.

• · Annual Meeting will be held virtually via audio conference call on July 14, 2025 (filed in 2026).
• · Record date for voting is May 19, 2026.
• · Proposals include election of directors, ratification of independent registered public accounting firm, and adjournment.
• · No outstanding preferred stock as of record date.
• · Proxy materials first mailed on or about May 29, 2026.

27-05-2026

Netskope Inc. filed a definitive proxy statement (DEF 14A) for its fiscal year 2026 annual meeting of stockholders, to be held virtually on July 7, 2026. The meeting will include the election of two Class I directors and the ratification of KPMG LLP as the independent auditor for fiscal year ending January 31, 2027. As of the record date of May 11, 2026, the company had 237,558,044 shares of Class A common stock and 166,109,471 shares of Class B common stock outstanding, with Class B shares carrying 20 votes per share versus one vote per Class A share.

• · The annual meeting will be held virtually on July 7, 2026 at 11:00 a.m. Pacific Time via live audio webcast at www.virtualshareholdermeeting.com/NTSK2026.
• · Stockholders of record as of May 11, 2026 are entitled to vote; each Class A share has one vote and each Class B share has 20 votes.
• · Proposal 1: Election of two Class I directors to hold office until the 2029 annual meeting.
• · Proposal 2: Ratification of KPMG LLP as independent auditor for fiscal year ending January 31, 2027.
• · The Board recommends a vote 'FOR' both proposals.
• · Quorum requires a majority of voting power of outstanding capital stock entitled to vote.
• · Proxy materials first sent on or about May 27, 2026.

27-05-2026

A Joint Special Meeting of Shareholders of the First Foundation Fixed Income Fund and First Foundation Total Return Fund is scheduled for July 10, 2026, to vote on a new investment sub-advisory agreement with First Foundation Advisors. The meeting is required because the all-stock merger of First Foundation Inc. into FirstSun Capital Bancorp (closed April 1, 2026) triggered a change of control under the 1940 Act, automatically terminating the prior sub-advisory agreement. The Board unanimously recommends voting FOR the new agreement, which has the same sub-advisory fee and substantially identical terms as the prior agreement, and no changes to fund objectives, strategies, or portfolio managers are expected.

• · Record date for voting is May 8, 2026.
• · Meeting will be held at SEI Investments, One Freedom Valley Drive, Oaks, PA 19456 at 11:00 a.m. Eastern time.
• · The all-stock merger was announced on October 27, 2025, and closed on April 1, 2026.
• · The Interim Sub-Advisory Agreement became effective on the Closing Date (April 1, 2026) and lasts up to 150 days.
• · If the New Sub-Advisory Agreement is not approved, the Board may resubmit it or consider other alternatives.
• · Proxy solicitation costs of approximately $25,129 will be borne by First Foundation.
• · Shareholders can vote by mail, Internet, telephone, or in person.
• · Proxy solicitor EQ Fund Solutions can be reached at (800) 820-2416.

27-05-2026

Translational Development Acquisition Corp. (TDACW) filed a DEF 14A proxy statement on May 27, 2026, seeking shareholder approval to extend the deadline to complete an initial business combination beyond the current Deadline Date, with potential extensions up to June 24, 2027, supported by sponsor deposits of up to $200,000 per month. The filing details redemption rights for public shareholders in connection with the extension, but warns that even if approved, there is no assurance a business combination will be consummated, and failure to do so would result in liquidation and warrants expiring worthless.

• · The initial shareholders have waived their rights to participate in any liquidation distribution with respect to Founder Shares.
• · If the Extension Amendment is not approved and no business combination is completed, the company will redeem Public Shares and dissolve/liquidate, with warrants expiring worthless.
• · Shareholders are not being asked to vote on the Proposed Business Combination at this Extraordinary General Meeting; a separate vote will occur later.
• · The Sponsor is not obligated to fund the Trust Account for extensions; if some affiliates decide to extend, they may deposit the entire required amount.
• · U.S. federal income tax treatment of redemptions depends on whether the redemption qualifies as a sale under Section 302 of the Code or as a distribution under Section 301.
• · The company may not be able to distribute Trust Account proceeds due to claims of creditors that may take priority over public shareholders.

27-05-2026

Estrella Immunopharma, Inc. filed a definitive proxy statement (DEF 14A) for its Combined 2025/2026 Annual Meeting of Stockholders to be held virtually on June 29, 2026. The sole proposal is to ratify the appointment of Macias Gini & O’Connell LLP as the independent registered public accounting firm for fiscal year ending December 31, 2026. No directors are being elected as there are no Class I directors on the board.

• · The annual meeting will be held virtually on June 29, 2026 at 10:00 a.m. Eastern Time.
• · Record date for voting is May 20, 2026.
• · Proxy materials are being distributed on or about May 27, 2026.
• · Stockholders may vote by mail, Internet, telephone, or live during the virtual meeting.
• · The meeting serves as the annual meeting for both fiscal year 2025 and fiscal year 2026.
• · No Class I directors are on the board, so no director elections are scheduled.

27-05-2026

Live Oak Acquisition Corp. V (LOKVU) is seeking shareholder approval for its business combination with Teamshares, a company that will become the combined entity's only significant asset. The Live Oak Board did not obtain a fairness opinion from an independent third party, relying instead on its own financial analyses and management's due diligence, which introduces significant valuation risk for public shareholders. There is no specified maximum redemption threshold, meaning Live Oak could complete the deal even if a substantial majority of public shareholders disagree and redeem their shares, potentially reducing the trust account and public float.

• · The Live Oak Board did not obtain a fairness opinion or any similar report from an independent investment banking or accounting firm regarding the fairness of the Business Combination.
• · Live Oak has no specified maximum redemption threshold, allowing the deal to proceed even if a substantial majority of public shareholders disagree and redeem their shares.
• · The Sponsor, directors, executive officers, advisors, and their affiliates may purchase shares or warrants from public shareholders prior to the consummation of the Business Combination, potentially influencing the vote and reducing the public float.
• · Any such purchases will be disclosed in a Form 8-K filing prior to the extraordinary general meeting, including the amount, price, purpose, impact on approval likelihood, identities of sellers, and number of redemption requests received.
• · During the pendency of the Business Combination, both Live Oak and Teamshares are restricted from entering into other business combinations due to covenants in the Merger Agreement.